Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing differentiated antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. Adagio believes their antibodies have the potential to match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and to be used as both therapeutic and durable prophylactic treatments. The candidates are engineered using industry-leading antibody discovery capabilities and are designed to maximize potency and duration of effect. The Adagio portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape.